SUMO2 inhibits ACSL3 protein degradation to antagonize erastin-induced ferroptosis in hepatocellular carcinoma
Abstract Hepatocellular carcinoma (HCC) is the prevalent form of primary liver cancer with a high rate of morbidity and death. Ferroptosis is a kind of regulatory cell death mode that depends on iron. Small ubiquitin-like modifier 2 (SUMO2) is linked to HCC progression; however, its role in ferropto...
Saved in:
| Main Authors: | Yanxi Shen, Bin Ye, Chuanfei Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02921-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ferroptosis inducers – erastin and analogues (review)
by: E. V. Sanarova, et al.
Published: (2024-06-01) -
Metabolic consequences of erastin-induced ferroptosis in human ovarian cancer cells: an untargeted metabolomics study
by: Kaylie I. Kirkwood-Donelson, et al.
Published: (2025-01-01) -
COP1 drives renal cell carcinoma progression by targeting ACSL4 for ubiquitin-mediated degradation and inhibiting ferroptosis
by: Yuxiao Zheng, et al.
Published: (2025-05-01) -
Potential role of SUMO-specific proteases 1 in ferroptosis
by: XIE Bin, et al.
Published: (2025-01-01) -
GABPA inhibits tumorigenesis in clear cell renal cell carcinoma by regulating ferroptosis through ACSL4
by: Yaqian Wu, et al.
Published: (2024-11-01)